myriad_S_stacked.png
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
December 10, 2024 08:00 ET | Myriad Genetics, Inc.
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
myriad_S_stacked.png
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
December 09, 2024 08:00 ET | Myriad Genetics, Inc.
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.